NASDAQ:MNPR Monopar Therapeutics (MNPR) Stock Price, News & Analysis $69.00 -1.29 (-1.84%) Closing price 11/20/2026 04:00 PM EasternExtended Trading$67.16 -1.84 (-2.67%) As of 11/20/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Monopar Therapeutics Stock (NASDAQ:MNPR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Monopar Therapeutics alerts:Sign Up Key Stats Today's Range$67.36▼$69.8650-Day Range$66.28▼$108.3252-Week Range$50.07▼$124.82Volume132,610 shsAverage Volume153,440 shsMarket Capitalization$467.82 millionP/E RatioN/ADividend YieldN/APrice Target$123.13Consensus RatingModerate Buy Company Overview Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. Its pipeline includes radiopharmaceutical candidates designed to target the urokinase plasminogen activator receptor (uPAR), a protein found at elevated levels in some cancers. The company is developing MNPR-101-Zr as an imaging agent to identify uPAR-expressing tumors and MNPR-101-Lu as a potential targeted radiation therapy. These candidates are investigational and are not approved for commercial use. Monopar is based in the United States and is led by co-founder and Chief Executive Officer Chandler Robinson. Its work is focused on research and clinical development rather than marketing approved products.AI Generated. May Contain Errors. Read More Monopar Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks54th Percentile Overall ScoreMNPR MarketRank™: 2.69375 of 5 starsMonopar Therapeutics scored higher than 54% of companies evaluated by MarketBeat, and ranked 421st out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingMonopar Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialMonopar Therapeutics has a consensus price target of $123.13, representing about 78.4% upside from its current price of $69.00.Amount of Analyst CoverageMonopar Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Monopar Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Monopar Therapeutics are expected to decrease in the coming year, from ($2.64) to ($5.19) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Monopar Therapeutics is -28.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Monopar Therapeutics is -28.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMonopar Therapeutics has a P/B Ratio of 3.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted18.21% of the float of Monopar Therapeutics has been sold short.Short Interest Ratio / Days to CoverMonopar Therapeutics has a short interest ratio ("days to cover") of 8.8.Change versus previous monthShort interest in Monopar Therapeutics has recently decreased by 2.22%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMonopar Therapeutics does not currently pay a dividend.Dividend GrowthMonopar Therapeutics does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.63 News SentimentMonopar Therapeutics has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Monopar Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for MNPR on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Monopar Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,527,913.00 in company stock.Percentage Held by Insiders9.70% of the stock of Monopar Therapeutics is held by insiders.Percentage Held by Institutions1.83% of the stock of Monopar Therapeutics is held by institutions.Read more about Monopar Therapeutics' insider trading history. Receive MNPR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Monopar Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MNPR Stock News HeadlinesMonopar Therapeutics (NASDAQ:MNPR) Stock Rating Raised to Hold at Wall Street ZenNovember 21 at 1:18 AM | americanbankingnews.comBrookline Capital Markets Weighs in on MNPR FY2026 EarningsNovember 19 at 1:42 AM | americanbankingnews.comThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This past May, flooding cut the supply route into the largest uranium complex on the planet, and in July Cigar Lake went down a second time. Gerardo Del Real calls this the Third Convergence Event and has backed three small companies positioned in front of it.November 21 at 1:00 AM | Digest Publishing (Ad)Monopar Therapeutics (NASDAQ:MNPR) Stock Gets Price Target Boost from Morgan StanleyNovember 18 at 2:48 AM | americanbankingnews.comQ1 Earnings Forecast for MNPR Issued By HC WainwrightNovember 15, 2026 | americanbankingnews.comMonopar Therapeutics (NASDAQ:MNPR) Stock Moved Up to "Overweight" by Cantor FitzgeraldNovember 13, 2026 | americanbankingnews.comMonopar Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 12, 2026 | marketscreener.comMMonopar Therapeutics (NASDAQ:MNPR) Stock: Insider Kim Tsuchimoto Sells 1,199 SharesNovember 5, 2026 | insidertrades.comSee More Headlines MNPR Stock Analysis - Frequently Asked Questions How have MNPR shares performed this year? Monopar Therapeutics' stock was trading at $65.30 at the start of the year. Since then, MNPR stock has increased by 5.7% and is now trading at $69.00. How were Monopar Therapeutics' earnings last quarter? Monopar Therapeutics Inc. (NASDAQ:MNPR) posted its quarterly earnings results on Thursday, November, 12th. The company reported ($0.72) EPS for the quarter, missing analysts' consensus estimates of ($0.72) by $0.00. When did Monopar Therapeutics' stock split? Monopar Therapeutics shares reverse split on Tuesday, August 13th 2024.The 1-5 reverse split was announced on Friday, August 9th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. Does Monopar Therapeutics have any subsidiaries? Monopar Therapeutics subsidiaries include these companies: Monopar Therapeutics Pty Ltd, and Monopar Therapeutics SARL. When did Monopar Therapeutics IPO? Monopar Therapeutics (MNPR) raised $9 million in an initial public offering (IPO) on Thursday, December 19th 2019. The company issued 1,100,000 shares at a price of $8.00 per share. JonesTrading acted as the underwriter for the IPO and Arcadia Securities was co-manager. Who are Monopar Therapeutics' major shareholders? Top institutional shareholders of Monopar Therapeutics include State Street Corp (3.42%), Candriam S.C.A. (1.93%), Goldman Sachs Group Inc. (1.31%) and American Century Companies Inc. (0.08%). Insiders that own company stock include Tactic Pharma Llc, Chandler Robinson, Andrew Cittadine, Raymond Anderson, Christopher M Starr, Karthik Radhakrishnan, Quan Anh Vu and Kim R Tsuchimoto. View institutional ownership trends. How do I buy shares of Monopar Therapeutics? Shares of MNPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Monopar Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Monopar Therapeutics investors own include NVIDIA (NVDA), SoundHound AI (SOUN), NIO (NIO), Palantir Technologies (PLTR), Viking Therapeutics (VKTX), BigBear.ai (BBAI) and Advanced Micro Devices (AMD). Company Calendar Last Earnings11/12/2026Today11/21/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (24m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 MNPR's financial health is in the Green zone, according to TradeSmith. MNPR has been in this zone for over 24 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:MNPR CIK1645469 Webwww.monopartx.com Phone847-388-0349FaxN/AEmployees22Year Founded2014Price Target and Rating Average Price Target for Monopar Therapeutics$123.13 High Price Target$145.00 Low Price Target$100.00 Potential Upside/Downside+78.4%Consensus RatingModerate Buy Rating Score (0-4)2.63 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($2.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$13.72 million Net MarginsN/A Pretax MarginN/A Return on Equity-15.52% Return on Assets-15.15% Debt Debt-to-Equity RatioN/A Current Ratio43.56 Quick Ratio43.56 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$18.75 per share Price / Book3.68Miscellaneous Outstanding Shares6,780,000Free Float6,120,000Market Cap$467.82 million OptionableNot Optionable Beta1.62 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:MNPR) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored432 miles southeast of Washington, DC…Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip mak...Wall Street Watchdogs | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monopar Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monopar Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.